Multicentre randomised double-blinded placebo-controlled trial of favipiravir in adults with mild COVID-19
경증 COVID-19 성인을 대상으로 한 favipiravir의 다기관 무작위 이중 맹검 위약 대조 시험
Article
[키워드] 1:1
Affair
approved
blinded
by mouth
caused
clinical
clinical trials
control group
Coronavirus infection
COVID-19
COVID-19 sample
Cox proportional hazard regression
decrease
diagnosed
disease onset
double-blind
double-blinded
dropout rate
Efficacy and safety
Eligible participants
Ethics
evaluate the effect
evaluated
Evidence
Favipiravir
follow-up period
followed by
hazard ratio
healthcare
hypothesise
Infectious diseases
institutional review board
intention to treat
International
King
lack
limit
medication
men
Mild
Ministry of Health
mouth
nonpregnant
Novel coronavirus
outbreak
outcome
participant
Patient
PCR
PCR test
peer-reviewed
per day
physician
Placebo
placebo-controlled trial
positive
potential therapy
primary analysis population
Primary outcome
randomised
Randomised trial
recruit
recruited
registration number
registry
reported
required
Respiratory illness
SARS-CoV-2
subject
swab sample
symptomatic patient
Symptomatic patients
the timing
therapeutic agent
Therapeutics
therapy
treat
treated
Treatment
Virology
virus
virus clearance
women
[DOI] 10.1136/bmjopen-2020-047495 PMC 바로가기 [Article Type] Article
[DOI] 10.1136/bmjopen-2020-047495 PMC 바로가기 [Article Type] Article